---
figid: PMC11215755__nihms-2000887-f0002
pmcid: PMC11215755
image_filename: nihms-2000887-f0002.jpg
figure_link: /pmc/articles/PMC11215755/figure/F2/
number: Fig. 2 |
figure_title: Drugging the PI3K pathway through the decades
caption: Timeline summarizing phosphatidylinositol 3-kinase (PI3K) pathway inhibitor
  drug development. FDA-approved drugs and their indications are boxed. CLL, chronic
  lymphocytic leukaemia; FL, follicular lymphoma; HR, hormone receptor; MZL, marginal
  zone lymphoma; NETs, neuroendocrine tumours; PIKK, PI3K-related kinase; RCC, renal
  cell carcinoma; R/R, relapse and/or refractory; SLL, small lymphocytic lymphoma.
article_title: 'At a crossroads: how to translate the roles of PI3K in oncogenic and
  metabolic signalling into improvements in cancer therapy.'
citation: Neil Vasan, et al. Nat Rev Clin Oncol. ;19(7):471-485.
year: '2024'

doi: 10.1038/s41571-022-00633-1
journal_title: Nature reviews. Clinical oncology
journal_nlm_ta: Nat Rev Clin Oncol
publisher_name: ''

keywords:
---
